Form 8-K - Current report:
SEC Accession No. 0001326190-23-000003
Filing Date
2023-02-28
Accepted
2023-02-28 07:04:17
Documents
15
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20230228x8k.htm   iXBRL 8-K 44081
2 EX-99.1 alt-20230228xex99d1.htm EX-99.1 177176
3 GRAPHIC alt-20230228xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-23-000003.txt   454870

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20230228.xsd EX-101.SCH 3252
5 EX-101.LAB alt-20230228_lab.xml EX-101.LAB 634
6 EX-101.PRE alt-20230228_pre.xml EX-101.PRE 10461
9 EXTRACTED XBRL INSTANCE DOCUMENT alt-20230228x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 23678319
SIC: 2834 Pharmaceutical Preparations